|Ms. Vered Caplan M.Sc.||Chairperson of the Board, CEO & President||335.97k||875.75k||1969|
|Prof. Sarah Ferber Ph.D.||Founder & Chief Scientific Officer||268.32k||N/A||1954|
|Mr. Elliot Maltz CPA||Chief Financial Officer||N/A||N/A||1984|
|Dan Slonim||COO & GM of Orgenesis Israel||N/A||N/A||N/A|
|Dr. Shimon Hassin Ph.D.||Chief Technology Officer||N/A||N/A||N/A|
|Ms. Osher Partok Rheinisch||General Counsel & Compliance Officer||N/A||N/A||1972|
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
Orgenesis Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.